Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
| Autor: | B. Mlineritsch, Michael Gnant, Werner Kwasny, Ferdinand Ploner, Christian F. Singer, Martin Moik, Michael Seifert, Georg Pfeiler, P. Sandbichler, Richard Greil, Peter Dubsky, Friedrich Hofbauer, U Selim, Hellmut Samonigg, Florian Fitzal, Marija Balic, Christian Fesl, Raimund Jakesz, Herbert Stöger, Günther G. Steger, K Renner |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
obesity Cancer Research medicine.medical_specialty Antineoplastic Agents Hormonal Breast Neoplasms Receptors Cell Surface Overweight Body Mass Index law.invention BMI breast cancer Breast cancer Randomized controlled trial law Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Prospective Studies skin and connective tissue diseases Prospective cohort study Aged Aged 80 and over Gynecology tamoxifen Aromatase Inhibitors business.industry Middle Aged medicine.disease Aminoglutethimide Postmenopause Treatment Outcome Hormone receptor aromatase inhibitor Clinical Study Female medicine.symptom business Tamoxifen medicine.drug Hormone |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Background: There exists evidence that body mass index (BMI) impacts on the efficacy of aromatase inhibitors in patients with breast cancer. The relationship between BMI and the efficacy of tamoxifen is conflicting. We investigated the impact of BMI on the efficacy of single tamoxifen and tamoxifen plus an aromatase inhibitor in the well-defined prospective study population of the ABCSG-06 trial. Methods: ABCSG-06 investigated the efficacy of tamoxifen vs tamoxifen plus aminoglutethimide in postmenopausal women with hormone receptor-positive breast cancer. Taking BMI at baseline, patients were classified as normal weight (BMI=18.5–24.9 kg m−2), overweight (BMI=25–29.9 kg m−2), and obese (30 kg m−2) according to WHO criteria. Results: Overweight+obese patients had an increased risk for distant recurrences (hazard ratio (HR): 1.51; Cox P=0·018) and a worse overall survival (OS; HR: 1·49; Cox P=0·052) compared with normal weight patients. Analysing patients treated with single tamoxifen only, no difference between overweight+obese patients and normal weight patients regarding distant recurrence-free survival (HR: 1.35; Cox P=0·24) and OS (HR: 0.99; Cox P=0·97) could be observed. In contrast, in the group of patients treated with the combination of tamoxifen plus aminoglutethimide, overweight+obese patients had an increased risk for distant recurrences (1.67; Cox P=0·03) and a worse OS (1.47; Cox P=0·11) compared with normal weight patients. Conclusion: BMI impacts on the efficacy of aromatase inhibitor-based treatment but not single tamoxifen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|